Skip to main content Accessibility help
Hostname: page-component-8bbf57454-jcfbx Total loading time: 1.15 Render date: 2022-01-25T15:21:11.478Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Experimental rat models to study the metabolic syndrome

Published online by Cambridge University Press:  27 July 2009

Amaya Aleixandre de Artiñano*
Department of Pharmacology, Faculty of Medicine, Complutense University, 28040Madrid, Spain
Marta Miguel Castro
Department of Pharmacology, Faculty of Medicine, Complutense University, 28040Madrid, Spain Instituto de Fermentaciones Industriales (CSIC), Madrid, Spain
*Corresponding author: Amaya Aleixandre de Artiñano, fax +34 91 3941463, email
Rights & Permissions[Opens in a new window]


Being the metabolic syndrome a multifactorial condition, it is difficult to find adequate experimental models to study this pathology. The obese Zucker rats, which are homozygous for the fa allele, present abnormalities similar to those seen in human metabolic syndrome and are a widely extended model of insulin resistance. The usefulness of these rats as a model of non-insulin-dependent diabetes mellitus is nevertheless questionable, and they neither can be considered a clear experimental model of hypertension. Some experimental models different from the obese Zucker rats have also been used to study the metabolic syndrome. Some derive from the spontaneously hypertensive rats (SHR). In this context, the most important are the obese SHR, usually named Koletsky rats. Hyperinsulinism, associated with either normal or slightly elevated levels of blood glucose, is present in these animals, but SHR/N-corpulent rats are a more appropriated model of non-insulin-dependent diabetes mellitus. The SHR/NDmc corpulent rats, a subline of SHR/N-corpulent rats, also exhibit metabolic and histopathologic characteristics associated with human metabolic disorders. A new animal model of the metabolic syndrome, stroke-prone–SHR (SHRSP) fatty rats, was obtained by introducing a segment of the mutant leptin receptor gene from the Zucker line heterozygous for the fa gene mutation into the genetic background of the SHRSP. Very recently, it has been developed as a non-obese rat model with hypertension, fatty liver and characteristics of the metabolic syndrome by transgenic overexpression of a sterol-regulatory element-binding protein in the SHR rats. The Wistar Ottawa Karlsburg W rats are also a new strain that develops a nearly complete metabolic syndrome. Moreover, a new experimental model of low-capacity runner rats has also been developed with elevated blood pressure levels together with the other hallmarks of the metabolic syndrome.

Review Article
Copyright © The Authors 2009

The metabolic syndrome has been recognised in the medical literature for more than 80 years. The syndrome does not constitute one single illness. Instead, it can be defined as a group of health problems, caused by genetic and environmental factors, whose common fundamental pathogenic component is resistance to insulin. These problems may occur in one individual simultaneously or one by one, but their appearance together in one person is significant as these patients are more prone to CVD in general and to coronary disease in particular.

In its Third Panel of Adult Treatment, part of the National Program for Cholesterol Education, the U.S. National Health Institute gave a definition of the metabolic syndrome based on risk factors, which is straightforward to apply in epidemiological studies and daily clinical practice(Reference Burton-Freeman1). This definition does not require direct demonstration of resistance to insulin, which in clinical practice may be difficult to establish. The metabolic syndrome is assumed to exist when three or more of the following risk factors: abdominal obesity, high TAG, low cholesterol in the HDL, hyperglycaemia, while fasting and hypertension.

Being a multifactorial condition, different treatments should be used for the different patients with the metabolic syndrome, and it is impossible in the practice to develop animal strains that represent all the different patients with this syndrome. It is in fact nowadays a challenge to find adequate experimental models to study the metabolic syndrome, but some animal strains, and in particular some rat strains, with a profile of anomalies quite similar to those that characterise the majority of the patients with this syndrome, could permit nowadays to evaluate the drugs and lifestyle interventions to treat or prevent it. At the present moment, the most representative rat strain to study the metabolic syndrome seems to be the obese Zucker rats. These animals are mainly used as obesity experimental model, but they also present changes similar to those seen in human metabolic syndrome. Some experimental models different from the obese Zucker rats have also been used to study the pathogenesis, therapy and prevention of obesity, and some of them can also be used to study the metabolic syndrome. In the present review, we put forward a detailed account of the changes observed in the obese Zucker rats, with particular regard to those which characterise the aforementioned syndrome, and we also present other rat strains with these abnormalities. Some of them derive from the spontaneously hypertensive rats (SHR).

The present review is finally focused on experimental rat models to study the metabolic syndrome, but it is also advisable to warn that other additional animal models, and in particular Psammomys obesus and some mouse strains, as the leptin-deficient (ob/ob) mice, the apoE-deficient mice or diet-induced obesity mice also present anomalies similar to those of the metabolic human syndrome and could therefore be used to study it.

Obese Zucker rats

Obese Zucker rats are the best known and most widely used animal model of genetic obesity. The fa mutation was discovered in 1961 by Lois Zucker in a cross between Merck M-strain and Sherman rats(Reference Zucker and Zucker2). The animals that are homozygous for the fa allele, the fa/fa Zucker rats, better known as obese Zucker rats, become noticeably obese between the third and the fifth week of life. These animals present a mutation in the leptin receptor, which is the molecular base of their characteristic phenotype(Reference Chua, Chung and Wupeng3Reference Phillips, Liu and Hammond5). Leptin is produced by adipose tissue and plays an important role in the central regulation of energy balance(Reference Zhang, Proenca and Maffei6). This hormone is released into the circulatory system by the adipose tissue in proportion to the amount of lipids stored and acts in the brain on the leptin receptors, determining a decrease in food intake and an increase in energy expenditure(Reference Ahima and Flier7Reference Palou, Serra and Bonet9). A direct or indirect consequence of the lack of a leptin receptors-mediated counter-regulation is that obese Zucker rats display markedly elevated circulating leptin levels compared with their lean counterparts(Reference Hardie, Rayner and Holmes10, Reference Picó, Sánchez and Oliver11). Old classical orexigenic peptides such as neuropeptide Y, galanin, orexins and melanin-concentrating hormone are upregulated in obese Zucker rats(Reference Beck12Reference Stricker-Krongrad, Dimitrov and Beck15). Concretely, this strain is characterised by an increased expression of ghrelin both at the peripheral and central levels(Reference Beck, Richy and Stricker-Krongrad16, Reference Beck, Richy and Stricker-Krongrad17). This fact could be participating in the development of extra weight in the obese Zucker rats.

The obese Zucker rats develop severe obesity associated with hyperphagia, defective non-shivering thermogenesis and preferential deposition of energy in adipose tissue(Reference Chua, Chung and Wupeng3). By 14 weeks of life, body composition of the obese Zucker rats is approximately 40 % weight lipid(Reference Zucker and Zucker18Reference Zucker and Antoniades20). The affected rats develop hyperplasia and adipocyte hypertrophy(Reference Johnson, Zucker and Cruce21).

In addition to their characteristic obesity, obese Zucker rats present a range of endocrinological abnormalities. In reality, these animals are a widely extended model of insulin resistance, presenting very similar features to those characterising human metabolic syndrome. In fact, as well as resistance to the metabolic actions of insulin, these animals present dyslipidaemia, mild glucose intolerance and hyperinsulinaemia(Reference Zucker and Zucker18Reference Muller and Cleary25). Hyperinsulinaemia is detectable at 3 weeks and persists throughout the animals' lives, the islets of Langerhans' hypertrophy moderately and increase in number. In addition, the animals present renal damage(Reference Kasiske, O'Donnell and Keane26).

At 17 d, obese Zucker rats can already be seen to eat more compared with lean animals from the same litter(Reference Stern and Johnson27). Hyperphagia is particularly apparent during the growth period of the obese animals, i.e. during the first 16 weeks of life(Reference Vasselli, Cleary and Jen28). Some pharmacological treatments, naloxone(Reference Thornhill, Taylor and Marshall29), d-amphetamine and fenfluramine(Reference Grinker, Drewnowski and Enns30), acarbose(Reference Vasselli, Haraczkiewicz and Maggio31) and cholecystokinin(Reference Maggio, Haraczkiewicz and Vasselli32) among others and dietary manipulations have succeeded in reducing hyperphagia in these animals to a varying degree, but have not managed to normalise the obese body composition. Lifelong food intake restriction results in a reduction in these animals' body weight, but the bodies of obese Zucker rats always continue to maintain a proportion of lipids of approximately 50 %. This percentage is much greater than the percentage of lipids found in the bodies of lean littermates (20 %)(Reference Cleary, Vasselli and Greenwood33). We also know that, when energy intake is reduced, these animals respond with a decrease in the number of fat cells rather than a decrease in the volume of these cells(Reference Hausman, Fine and Tagra34).

Different studies suggest that the activity of adipose tissue lipoprotein lipase activity, which is significantly correlated with enhanced TAG uptake by adipose tissue, is one of the candidates for the primary lesion produced by the presence of the fa gene in Zucker rats. The increase in this enzyme's activity may correlate with enhanced TAG uptake by adipose tissue(Reference Maggio and Greenwood35). Lipase lipoprotein activity, which controls lipid filling of adipocytes, is elevated in 12-d-old animals, in other words well before the animals can be visually identified as obese(Reference Gruen, Hietanen and Greenwood36). This change precedes other determining factors of obesity, such as enhanced liver lipogenesis and hyperinsulinaemia(Reference Turkenkopf, Olsen and Moray37Reference Greenwood39).

The amount of blood per unit of body weight in obese Zucker rats is lower than normal. The plasma of these animals is milky in appearance, as its fatty acid and cholesterol contents are ten and four times greater than normal, respectively. In reality, these rats present a hepatic overproduction of lipoproteins. The increase of lipids and lipoproteins in plasma is also one of the first anomalies to be observed in the rats(Reference Zucker40Reference Witztum and Schonfeld45). They show an increase in VLDL and in HDL but although they present a decrease in the expression of hepatic receptors for LDL, they show no increase in LDL-cholesterol and cannot be used as a model of atherogenesis(Reference Liao, Angelin and Rudling46). Like other rodents, they have larger amounts of HDL than LDL, but an increase in LDL-cholesterol can be induced in these animals by means of dietary supplements of saturated fats and cholesterol(Reference Vaskonen, Mervaala and Seppänen-Laakso47). Thus the increase in TAG concentration in plasma exhibited by obese Zucker rats is due to the accumulation of VLDL, and the increase in cholesterol is due to the increase in cholesterol in the VLDL and HDL fractions. The increase in HDL-cholesterol is particularly manifest in the male rats(Reference Lin48). In fact, in 1985, Lin described clear differences between obese males and females. This researcher showed that the increase in the serum cholesterol of obese females was caused principally by its high content of non-esterified cholesterol associated with VLDL. By contrast, in males, serum cholesterol was chiefly transported as esters of cholesterol with HDL.

These rat glucose levels are in reality normal or only slightly higher than normal. Therefore, these animals are not the best model to study the effective treatments to control alterations of glucose homeostasis. Nevertheless, some researchers have succeeded in identifying several vascular changes characteristic of diabetes in these rats(Reference Lash, Sherman and Hamlin49). The lipid profile of lean Zucker rats is similar to that of Sprague–Dawley(Reference Zucker40, Reference Barry and Bray41) and Wistar(Reference Schonfeld and Pfleger42) rats. These animals are sensitive to insulin, are normotensive and have a normal glucose tolerance.

The link between obesity and hypertension has been recognised for some time. Several studies have reported conflicting results about whether obese Zucker rats are hypertensive compared with their lean controls(Reference Ernsberger and Nelson50Reference Kurtz, Morris and Pershadsingh62). Systolic arterial blood pressure in obese rats is lower than that in control lean rats of between 8 and 12 weeks of life. At 24 weeks, the phenomenon goes into reverse, and at 28 weeks, systolic arterial blood pressure in obese rats is significantly higher than in their lean counterparts. With these observations in mind, Kurtz et al. (53) indicated that obese Zucker rats could be considered a model of obesity and hypertension. These animals could constitute an experimental model in which hypertension was specifically associated with the genotype for obesity. The increase in arterial blood pressure in the obese animals is not due to an increase in renal Na retention(Reference Kurtz, Morris and Pershadsingh62). The impaired vascular responses to acetylcholine that has been observed in some studies in the oldest obese Zucker rats indicate that endothelial dysfunction could justify, at least in part, the increased arterial blood pressure in these animals(Reference Subramanian and MacLeod63). There is evidence for a local angiotensin II-generating system in adipose tissue(Reference Harte, McTernan and Chetty64Reference Griendling, Sorescu and Ushio-Fukai66), implying that the vasoactive component angiotensin II may be produced by adipose tissue. Angiotensin II is a powerful stimulus for the generation of reactive oxygen species in the blood vessels(Reference Dzau67, Reference Unger and Gohlke68). This increased oxidative stress may interact with NO function, leading to endothelial dysfunction(Reference De Gasparo69). Therefore, we can also assume that the increased proportion of adipose tissue in the obese Zucker rats, and consequently the increased production of angiotensin II and reactive oxygen species, could facilitate the development of hypertension and endothelial dysfunction in these animals.

Obesity is also associated with a state of chronic inflammation characterised by abnormal production of proinflammatory mediators(Reference Ouchi, Kihara and Funahashi70), including TNF-α(Reference Hotamisligil, Shargill and Spiegelman71, Reference Hotamisligil, Arner and Caro72)and inducible NO synthase(Reference Perreault and Marette73). This inflammatory state is associated with a deficit of energy in the form of ATP(Reference Wlodek and Gonzales74, Reference Boudina, Sena and O'Neill75)and simultaneous overproduction of fat and leptin, which is accompanied by leptin resistance in the brain(Reference Wlodek and Gonzales74, Reference Munzberg and Myers76). Recent studies have shown that fat tissue is not a simple energy storage organ, but exerts important endocrine and immune functions. These are achieved predominantly through the release of several factors termed ‘adipocytokines’, which include several novel and highly active molecules released abundantly by adipocytes like above-mentioned leptin, as well as some more classical cytokines released possibly by inflammatory cell infiltrating fat like, TNF-α, IL-6, monocyte chemotactic protein-1 and IL-1(Reference Tilg and Moschen77). In this context, TNF-α, a proinflammatory cytokine, is overexpressed in obesity and likely mediates insulin resistance in the major animal models of obesity(Reference Hotamisligil, Shargill and Spiegelman71), including obese Zucker rats(Reference Picchi, Gao and Belmadani78). Both research groups postulated that overexpression of TNF-α induces the activation of NADPH oxidase and production of superoxide anion leading to endothelial dysfunction in obese Zucker rats.

Obese spontaneously hypertensive rats

The SHR, a well-known experimental model to study hypertension, have been also proposed as a model of insulin resistance. These rats show hypertriacylglycerolaemia, abdominal obesity and hypertension(Reference Reaven, Chang and Hoffman79, Reference Kvetnanský, Rusnák and Gasperíková83). In the background of SHR, different strains of corpulent SHR, such as obese SHR named, Koletsky rats, SHR/N-corpulent rats and SHR/NDmc-corpulent rats, seem to be even more adequate to study the metabolic syndrome than the SHR. The leptin receptor gene is also knocked out in these rats.

Obese spontaneously hypertensive rats/Koletsky rats

The obese SHR usually named Koletsky rats are considered an animal model with phenotypic features that strongly resemble metabolic syndrome X(Reference Ishizuka, Ernsberger and Liu84, Reference Ernsberger, Ishizuka and Liu85). This strain was originally established in 1970 by Koletsky(Reference Koletsky86Reference Kastin, Pan and Maness88) and presents obesity, hypertension, hyperinsulinaemia, hyperlipidaemia and nephropathy superimposed on the background of SHR. The abnormal animal was derived by mating a female SHR of the Wistar–Kyoto strain with a normotensive Sprague–Dawley male. The obese rat appeared after several generations of selective inbreeding of hypertensive offspring of the original cross. The SHROB has monogenetic obesity superimposed on a hypertensive genetic background. The obesity mutation is a recessive trait, designated fa k, which is a non-sense mutation of leptin receptor gene resulting in a premature stop codon in the leptin receptor extracellular domain. The SHROB carries two fa k alleles, is leptin resistant and has circulating leptin levels 30-fold higher that its lean siblings. This mutation renders the SHROB incapable of central and peripheral responses to leptin(Reference Koletsky89). Animals can be identified as genetically obese at about 5 weeks of age. Body weight increases rapidly, and males usually attain weight of 750–1000 g when 7–12 months old. Although both sexes are involved, males are heavier that females at practically all ages. The rats uniformly develop hyperlipidaemia even though they are fed with standard diet, which was characterised by a marked triacylglycerolaemia and a moderate rise in plasma cholesterol. The animals exhibit hyperphagia and also have abnormal carbohydrate and protein metabolism. Hyperinsulinism is present in these rats and is associated with either normal or slightly elevated level of blood glucose. Spontaneous hypertension usually occurs at about 3 months of age. The arterial blood pressure rises progressively at 8 and 12 weeks of age, achieving more than 180 mm Hg, and rises progressively to 200 mm Hg between 20 and 30 weeks of age. These animals also develop premature vascular disease involving especially abdominal arteries. Microscopically, the lesions occurred in this vessels simulate those of human atherosclerosis(Reference Kastin, Pan and Maness88).

Spontaneoulsy hypertensive/N corpulent rats

The spontaneously hypertensive/N-corpulent rats are a substrain of Koletsky rats that has been developed and characterised as a model for non-insulin-dependent diabetes mellitus(Reference Michaelis, Ellwood and Judge90). It has been demonstrated that obese SHR/N-corpulent rats male rats have some metabolic and histopathologic characteristics similar to non-insulin-dependent diabetes mellitus(Reference Michaelis, Patrick and Hansen91, Reference Michaelis, Carswell and Velasquez92). Obese rats are hyperinsulinaemic, hyperlipidaemic, glucose intolerant and exhibit glycosuria and proteinuria. Hyperglycaemia is observed in obese rats following an oral glucose load or postprandially, but not in the fasting state.

Spontaneoulsy hypertensive/NDmc-corpulent rats

The spontaneously hypertensive/NDmc-corpulent rats are an inbred subline of SHR/N-corpulent rats that also present obesity. This strain has also been used as an animal model for the metabolic syndrome(Reference Wexler, Iams and McMurtry93, Reference Hiraoka, Hosoda and Ogawa94). These animals are homozygous for the cp gene (cp/cp) and are hyperphagous and develop metabolic alterations, and they can be also named as (SHR-cp), whereas homozygous normal (+/+) animals are lean and hypertensive but not hyperlipidaemic and insulin resistant. The SHR-cp exhibit, in fact, metabolic and histopathologic characteristics associated with metabolic disorders in human subjects, such as increases in body and adipose tissue weights(Reference Baly, Zarnowski and Carswell95) accompanying hypertension and hypercardia(Reference Striffler, Bhathena and Michaelis96), diabetes(Reference Velasquez, Kimmel and Michaelis97, Reference Triana, Suits and Garrison98) and hyperlipidaemia(Reference Turley and Hansen99).

Stroke-prone–SHR fatty (fa/fa) rats

Stroke-prone SHR (SHRSP) are a rat model that develops severe hypertension. SHRSP rats develop hypertension-related disorders, such as nephropathy, cardiac hypertrophy and atherosclerosis, similar to human essential hypertension and 100 % die to stroke(Reference Yamori, Ohtaka and Horie100). As SHR rats, SHRSP is also a model of insulin resistance syndrome(Reference Reaven, Chang and Hoffman79, Reference Collins, Rodenbaugh and DiCarlo101). In spite of SHRSP being a good model of hypertension and insulin resistance, SHRSP weigh less than their normotensive control, Wistar–Kyoto rats, and have reduced plasma total cholesterol and NEFA levels. Very recently, Hiraoka-Yamamoto et al. (Reference Hiraoka-Yamamoto, Nara and Yasui102) have produced a new animal model of the metabolic syndrome, by introducing a segment of the mutant leptin receptor gene from the Zucker line heterozygous for the fa gene mutation, into the genetic background of the SHRSP. Therefore, a new congenic strain, SHRSP fatty (fa/fa) rats, was derived by replacing the fa locus of chromosome from Zucker (fa/fa) rats. The SHRSP fatty rats are characterised by the spontaneous development of hypertension, obesity, hyperleptinaemia and several metabolic disorders such as hyperlipidaemia and hyperinsulinaemia.

Sterol-regulatory element-binding protein–spontaneously hypertensive rats

The relationship between the metabolic syndrome and non-alcoholic fatty liver disease has recently begun to attract considerable attention(Reference Marchesini, Brizi and Bianchi103Reference den Boer, Voshol and Kuipers105). In subjects with clinical features of the metabolic syndrome, the prevalence of non-alcoholic fatty liver disease can be very high even in the absence of diabetes, obesity or abnormal liver enzymes. Moreover, 50 % of subjects with pure fatty liver and up to 90 % of subjects with non-alcoholic steatohepatitis have the metabolic syndrome according to Adult treatment panel III criteria(Reference Marchesini, Bianchi and Merli104). Although insulin resistance can be determinant of fatty liver, it has also been suggested that hepatic steatosis may play a role in the pathogenesis of the metabolic syndrome and promote insulin resistance in liver and skeletal muscle(Reference Diehl106Reference Samuel, Liu and Qu108). Some investigators have further proposed that non-alcoholic fatty liver disease may be considered an additional feature of the metabolic syndrome(120). Therefore, the availability of animal models with hepatic steatosis, as well as insulin resistance, dyslipidaemia and hypertension, could be valuable for studying the pathogenesis and treatment of the metabolic syndrome and its relationship to non-alcoholic fatty liver disease. Very recently, Qi et al. (Reference Horton, Goldstein and Brown109) have created a non-obese rat model with hypertension, fatty liver and characteristics of the metabolic syndrome by transgenic overexpression of a sterol-regulatory element-binding protein in the SHR rats. Sterol-regulatory element-binding proteins are transcription factors involved in the regulation of fatty acid and lipid metabolism and can activate the expression of multiple genes involved in the hepatic synthesis of cholesterol, TAG, fatty acids and phospholipids(Reference Horton, Goldstein and Brown110, Reference Horton, Shimomura and Ikemoto111). This indicates hepatic steatosis and multiple biochemical features of the metabolic syndrome, including hyperinsulinaemia, hyperglycaemia and hypertriacylglycerolaemia in the absence of obesity. The sterol-regulatory element binding protein–SHR model could therefore provide valuable opportunities for investigating pathogenetic mechanisms that may relate fatty liver disease to the metabolic syndrome.

Wistar Ottawa Karlsburg W rats

In 1995, a new inbred rat strain was developed, termed Wistar Ottawa Karlsburg W (WOKW) rats. These animals derived from a Wistar rat outbred strain of the BioBreeding Laboratories (Ottawa, Ont., Canada). The WOKW strain provides a good animal model expressing the metabolic syndrome. It is especially useful because their metabolic syndrome is under polygenic control, as in human subjects, and not due to a single-gene mutation(Reference Filippetti, Kloting and Massi112). The dark agouti rats are usually used as control animals of WOKW(Reference van den Brandt, Kovács and Klöting113). WOKW compared with dark agouti rats show hyperphagia, and are heavier and fatter. Segregating populations derived from this strain and inbred dark agouti rats have been successfully used to identify quantitative trait loci for major components of the metabolic syndrome, such as insulin resistance on WOKW chromosome 3 and hypertriacylglycerolaemia on WOKW chromosomes 4 and 6(Reference van den Brandt, Kovács and Klöting114, Reference Klöting, Kovács and van den Brandt115). The WOKW develops a nearly complete metabolic syndrome with obesity, moderate hypertension, dyslipidaemia, hyperinsulinaemia and impaired glucose tolerance(Reference van den Brandt, Kovács and Klöting114, Reference Kovács, van den Brandt and Klöting116, Reference Klöting, Vogt and Serikawa117). A cross-sectional comparative study indicated that the WOKW rat begins to manifest the signs of the metabolic syndrome between 8 and 10 weeks of age(Reference van den Brandt, Kovács and Klöting113). Very recently, the metabolic syndrome in WOKW rats has been also associated with coronary dysfunction(Reference Grisk, Frauendorf and Schlüter118). The dark agouti strain does not show any of these characteristics and has been considered as the control strain for the WOKW rats(Reference Filippetti, Kloting and Massi112, Reference van den Brandt, Kovács and Klöting113).

Low-capacity runner rats

Very recently, Wisløff et al. (Reference Wisløff, Najjar and Ellingsen119) have generated an animal model of the metabolic syndrome. To obtain this model, rats were selectively bred based on their ability to perform on a treadmill endurance running task. Accordingly, rats that have a high intrinsic aerobic capacity and are capable of running comparatively long distances are classified as high-capacity runner rats and are bred together. On the other hand, rats with a low intrinsic aerobic capacity that are only capable of running relatively short distances are classified as low-capacity runner (LCR) rats and are bred with each other. Eleven generations of selective breeding resulted in elevated blood pressure in LCR rats when compared with high-capacity runner rats. The LCR rats also show endothelial dysfunction, insulin resistance and hyperinsulinaemia, visceral adiposity, hypertriacylglycerolaemia and elevated plasma NEFA. Therefore, one advantage of this new experimental model is that elevated blood pressure in the LCR rats occurs together with the other hallmarks of the metabolic syndrome(Reference Wisløff, Najjar and Ellingsen119).


All rat models included in this review could be potentially used to study the metabolic syndrome. It is well known that this syndrome is not only one illness, but an association of health problems that are not coincident in all patients. The rat strains described in this review have a profile of anomalies quite similar to those that are present in the majority of these patients, but it is very important to exactly know the typical features or abnormalities of each strain, in order to correctly use them and to obtain the adequate information in the experimental trials. The obese Zucker rats have been extensively studied and are the best known animals to study the abnormalities present in the metabolic syndrome. More studies should be performed to characterise the other strains, in particular those that have been recently described as the LCR rats. Table 1 summarises the main characteristics of each one and could permit to adequately use them.

Table 1 Abnormalities that characterise the different rat stains that could be used to study the metabolic syndrome

SHR, spontaneously hypertensive rats.


There are no conflicts of interest to publish the present paper. We acknowledge Natraceutical Group for the financial support to carry out the projects UCM 206/2006 and UCM 36/2007 with obese Zucker rats and SHR. They permitted us to clarify the characteristics of these strains and their utility to study the metabolic syndrome. The present review has been prepared by Marta Miguel Castro and Amaya Aleixandre de Artiñano, and it was corrected for the final version by Amaya Aleixandre de Artiñano.


1Burton-Freeman, B (2000) Dietary fiber and energy regulation. J Nutr 130, 272S275S.CrossRefGoogle ScholarPubMed
2Zucker, LM & Zucker, TF (1961) Fatty, a new mutation in the rat. J Heredity 52, 275278.CrossRefGoogle Scholar
3Chua, SC, Chung, WK, Wupeng, XS, et al. (1996) Phenotypes of mouse diabetes and rat fatty due to mutations in the OB (leptin) receptor. Science 271, 994996.CrossRefGoogle ScholarPubMed
4Chua, SC Jr, White, DW, Wu-Peng, XS, et al. (1996) Phenotype of fatty due to Gln269Pro mutation in the leptin receptor (Lepr). Diabetes 45, 11411143.CrossRefGoogle Scholar
5Phillips, MS, Liu, QY, Hammond, HA, et al. (1996) Leptin receptor missense mutation in the fatty Zucker rat. Nature Gen 13, 1819.CrossRefGoogle ScholarPubMed
6Zhang, Y, Proenca, R, Maffei, M, et al. (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425432.CrossRefGoogle ScholarPubMed
7Ahima, RS & Flier, JS (2000) Leptin. Annu Rev Physiol 62, 413437.CrossRefGoogle ScholarPubMed
8Himms-Hagen, J (1999) Physiological roles of the leptin endocrine system; differences between mice and humans. Crit Rev Clin Lab Sci 36, 575655.CrossRefGoogle ScholarPubMed
9Palou, A, Serra, F, Bonet, ML, et al. (2000) Obesity: molecular bases of a multifactorial problem. Eur J Nutr 39, 127144.CrossRefGoogle ScholarPubMed
10Hardie, LJ, Rayner, DV, Holmes, S, et al. (1996) Circulating leptin levels are modulated by fasting, cold exposure and insulin administration in lean but not Zucker (fa/fa) rats as measured by ELISA. Biochem Biophys Res Commun 223, 660665.CrossRefGoogle Scholar
11Picó, C, Sánchez, J, Oliver, P, et al. (2002) Leptin production by the stomach is up-regulated in obese (fa/fa) Zucker rats. Obesity Res 10, 932938.CrossRefGoogle ScholarPubMed
12Beck, B (2000) Neuropeptides and obesity. Nutrition 16, 916923.CrossRefGoogle ScholarPubMed
13Beck, B, Burlet, A, Nicolas, JP, et al. (1990) Hyperphagia in obesity is associated with a central peptidergic dysregulation in rats. J Nutr 120, 806811.CrossRefGoogle ScholarPubMed
14Beck, B, Burlet, A, Nicolas, JP, et al. (1993) Galanin in the hypothalamus of fed and fasted lean and obese Zucker rats. Brain Res 623, 124130.CrossRefGoogle ScholarPubMed
15Stricker-Krongrad, A, Dimitrov, T & Beck, B (2001) Central and peripheral dysregulation of melanin-concentrating hormone in obese Zucker rats. Brain Res Mol 92, 4348.CrossRefGoogle ScholarPubMed
16Beck, B, Richy, S & Stricker-Krongrad, A (2004) Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats. Life Sci 76, 473478.CrossRefGoogle ScholarPubMed
17Beck, B, Richy, S & Stricker-Krongrad, A (2003) Ghrelin and body weight regulation in the obese Zucker rat in relation to feeding state and dark/light cycle. Exp Biol Med 228, 11241131.CrossRefGoogle ScholarPubMed
18Zucker, TF & Zucker, LM (1962) Hereditary obesity in the rat associated with high serum fat and cholesterol. Proc Soc Exp Biol Med 110, 165171.CrossRefGoogle Scholar
19Zucker, TF & Zucker, LM (1963) Fat accretion and growth in the rat. J Nutr 80, 619.Google ScholarPubMed
20Zucker, LM & Antoniades, HN (1972) Insulin and obesity in the Zucker genetically obese rat ‘fatty’. Endocrinology 90, 13201330.CrossRefGoogle Scholar
21Johnson, PR, Zucker, LM, Cruce, JA, et al. (1971) Cellularity of adipose depots in the genetically obese Zucker rat. J Lipid Res 12, 706714.Google ScholarPubMed
22Stern, J, Johnson, PR, Greenwood, MRC, et al. (1972) Insulin resistance and pancreatic insulin release in the genetically obese Zucker rat. Proc Soc Exp Biol Med 139, 6669.CrossRefGoogle ScholarPubMed
23Bryce, GF, Johnson, PR, Sullivan, AC, et al. (1977) Insulin and glucagon: plasma levels and pancreatic release in the genetically obese Zucker rat. Horm Met Res 9, 366370.CrossRefGoogle ScholarPubMed
24Ionescu, E, Sauter, JF & Jeanrenaud, B (1985) Abnormal glucose tolerance in genetically obese (fa/fa) rats. Am J Physiol 248, E500E506.Google ScholarPubMed
25Muller, S & Cleary, MP (1988) Glucose metabolism in isolated adipocytes from ad libitum- and restricted-fed lean and obese Zucker rats at two different ages. Proc Soc Exp Biol Med 187, 398407.CrossRefGoogle ScholarPubMed
26Kasiske, BL, O'Donnell, MP & Keane, WF (1992) The Zucker rat model of obesity, insulin resistance, hyperlipidemia, and renal injury. Hypertension 19, I110I115.CrossRefGoogle ScholarPubMed
27Stern, JS & Johnson, PR (1977) Spontaneous activity and adipose cellularity in the genetically obese Zucker rat (fafa). Metabolism 26, 371380.CrossRefGoogle Scholar
28Vasselli, JR, Cleary, MP, Jen, KLC, et al. (1980) Development of food motivated behavior in free feeding and food restricted Zucker fatty (fa/fa) rats. Physiol Behav 25, 565573.CrossRefGoogle ScholarPubMed
29Thornhill, JA, Taylor, B, Marshall, W, et al. (1982) Central, as well as peripheral naloxone administration suppresses feeding in food-deprived Sprague–Dawley and genetically obese (Zucker) rats. Physiol Behav 29, 841846.CrossRefGoogle ScholarPubMed
30Grinker, JA, Drewnowski, A, Enns, M, et al. (1980) Effects of d-amphetamine and fenfluramine on feeding patterns and activity of obese and lean Zucker rats. Pharmacol Biochem Behav 12, 265275.CrossRefGoogle ScholarPubMed
31Vasselli, JR, Haraczkiewicz, E, Maggio, CA, et al. (1983) Effects of a glucosidase inhibitor (acarbose, BAY g 5421) on the development of obesity and food motivated behavior in obese Zucker (fafa) rats. Pharmacol Biochem Behav 19, 8595.CrossRefGoogle ScholarPubMed
32Maggio, CA, Haraczkiewicz, E & Vasselli, JR (1988) Diet composition alters the satiety effect of cholecystokinin in lean and obese Zucker rats. Physiol Behav 43, 485491.CrossRefGoogle ScholarPubMed
33Cleary, MP, Vasselli, JR & Greenwood, MRC (1980) Development of obesity in Zucker obese (fafa) rat in absence of hyperphagia. Am J Physiol 238, E284E292.Google ScholarPubMed
34Hausman, DB, Fine, JB, Tagra, K, et al. (2003) Regional fat pad growth and cellularity in obese Zucker rats: modulation by caloric restriction. Obesity Res 11, 674682.CrossRefGoogle ScholarPubMed
35Maggio, CA & Greenwood, MRC (1982) Adipose tissue lipoprotein lipase (LPL) and triglyceride uptake in Zucker rats. Physiol Behav 29, 11471152.CrossRefGoogle ScholarPubMed
36Gruen, RK, Hietanen, E & Greenwood, MRC (1978) Increased adipose tissue lipoprotein lipase activity during the development of the genetically obese rat (fa/fa). Metabolism 27, 19551966.CrossRefGoogle Scholar
37Turkenkopf, IJ, Olsen, JL, Moray, L, et al. (1980) Hepatic lipogenesis in the preobese Zucker rat. Proc Soc Exp Biol Med 164, 530533.CrossRefGoogle ScholarPubMed
38Greenwood, MRC, Cleary, L & Steingrimsdottir, L (1981) Adipose tissue metabolism and genetic obesity: The LPL hypothesis. In Recent Advances in Obesity Research III, pp. 7579 [Bjorntorp, P, Cairella, M and Howard, AN, editors]. London: John Libbey.Google Scholar
39Greenwood, MRC (1985) Relationship of enzyme activity to feeding behavior in rats: lipoprotein lipase as the metabolic gatekeeper. Int J Obesity 9, 6770.Google ScholarPubMed
40Zucker, LM (1965) Hereditary obesity in the rat associated with hyperlipidemia. Ann N Y Acad Sci 131, 447458.CrossRefGoogle Scholar
41Barry, WS & Bray, GA (1969) Plasma triglycerides in genetically obese rats. Metabolism 18, 833839.CrossRefGoogle ScholarPubMed
42Schonfeld, G & Pfleger, B (1971) Overproduction of very low-density lipoproteins by livers of genetically obese rats. Am J Physiol 220, 11781181.Google ScholarPubMed
43Schonfeld, G, Felski, C & Howald, MA (1974) Characterization of the plasma lipoproteins of the genetically obese hyperlipoproteinemic Zucker fatty rat. J Lipid Res 15, 457464.Google ScholarPubMed
44Schirardin, H, Bach, A, Schaeffer, A, et al. (1979) Biological parameters of the blood in the genetically obese Zucker rat. Arch Intern Physiol Biochim 87, 275289.Google ScholarPubMed
45Witztum, JL & Schonfeld, G (1979) Lipoproteins in the plasma and hepatic perfusates of the Zucker fatty rat. Diabetes 28, 509516.CrossRefGoogle ScholarPubMed
46Liao, W, Angelin, B & Rudling, M (1997) Lipoprotein metabolism in the fat Zucker rat: reduced basal expression but normal regulation of hepatic low density lipoprotein receptors. Endocrinology 138, 32763282.CrossRefGoogle ScholarPubMed
47Vaskonen, T, Mervaala, E, Seppänen-Laakso, T, et al. (2001) Diet enrichment with calcium and magnesium enhances the cholesterol lowering effect of plant sterols in obese Zucker rats. Nutr Metab Cardiovasc Dis 11, 158167.Google ScholarPubMed
48Lin, RC (1985) Serum cholesterol, lecithin-cholesterol acyltransferase, and hepatic hydroxymethilglutaryl coenzyme A reductase activities of lean and obese Zucker rats. Metabolism 34, 1924.CrossRefGoogle ScholarPubMed
49Lash, JM, Sherman, WM & Hamlin, RL (1989) Capillary basement membrane thickness and capillary density in sedentary and trained obese Zucker rats. Diabetes 38, 854860.CrossRefGoogle ScholarPubMed
50Ernsberger, P & Nelson, DO (1988) Refeeding hypertension in dietary obesity. Am J Physiol 254, R47R55.Google ScholarPubMed
51Koletsky, S (1975) Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80, 129140.Google Scholar
52Zemel, MB, Sowers, JR, Shehin, S, et al. (1990) Impaired calcium metabolism associated with hypertension in Zucker obese rats. Metabolism 39, 704708.CrossRefGoogle ScholarPubMed
53Kurtz, TW, Morris, RC & Pershadsingh, HA (1989) The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13, 896901.CrossRefGoogle ScholarPubMed
54Kasiske, BL, Cleary, MP, O'Donnell, MP, et al. (1985) Effects of genetic obesity on renal structure and function in the Zucker rat. J Lab Clin Med 106, 598604.Google ScholarPubMed
55Wu, X, Mäkynen, H, Kähönen, M, et al. (1996) Mesenteric arterial function in vitro in three models of experimental hypertension. J Hypertens 14, 365372.CrossRefGoogle ScholarPubMed
56Yuen, VG, Pederson, RA, Dai, S, et al. (1996) Effects of low and high dose administration of bis(maltolato)oxovanadium(IV) on fa/fa Zucker rats. Can J Physiol Pharmacol 74, 10011009.CrossRefGoogle ScholarPubMed
57Arvola, P, Wu, X, Kähönen, M, et al. (1999) Exercise enhances vasorelaxation in experimental obesity associated hypertension. Cardiovasc Res 43, 9921002.CrossRefGoogle ScholarPubMed
58He, Y & MacLeod, KM (2002) Modulation of noradrenaline-induced vasoconstriction in isolated perfused mesenteric arterial beds from obese Zucker rats in the presence and absence of insulin. Can J Physiol Pharmacol 80, 171179.CrossRefGoogle ScholarPubMed
59Zanchi, A, Delacrétaz, E, Taleb, V, et al. (1995) Endothelial function of the mesenteric arteriole and mechanical behaviour of the carotid artery in rats with insulin resistance and hypercholesterolaemia. J Hypertens 13, 14631470.CrossRefGoogle ScholarPubMed
60Turner, NC & White, P (1996) Effects of streptozotocin-induced diabetes on vascular reactivity in genetically hyperinsulinaemic obese Zucker rats. J Cardiovasc Pharmacol 27, 884890.CrossRefGoogle ScholarPubMed
61Alonso-Galicia, M, Brands, MW, Zappe, DH, et al. (1996) Hypertension in obese Zucker rats. Role of angiotensin II and adrenergic activity. Hypertension 28, 10471054.CrossRefGoogle ScholarPubMed
62Kurtz, TW, Morris, RC & Pershadsingh, HA (1989) The Zucker fatty rat as a genetic model of obesity and hypertension. Hypertension 13, 896901.CrossRefGoogle ScholarPubMed
63Subramanian, R & MacLeod, KM (2003) Age-dependent changes in blood pressure and arterial reactivity in obese Zucker rats. Eur J Pharmacol 477, 143152.CrossRefGoogle ScholarPubMed
64Harte, A, McTernan, P, Chetty, R, et al. (2005) Insulin-mediated upregulation of the renin angiotensin system in human subcutaneous adipocytes is reduced by rosiglitazone. Circulation 111, 19541961.CrossRefGoogle ScholarPubMed
65Rajagopalan, S, Kurz, S, Münzel, T, et al. (1996) Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest 97, 19161923.CrossRefGoogle ScholarPubMed
66Griendling, KK, Sorescu, D & Ushio-Fukai, M (2000) NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86, 494501.CrossRefGoogle ScholarPubMed
67Dzau, VJ (1988) Molecular and physiological aspects of tissue renin-angiotensin system: emphasis on cardiovascular control. J Hypertens Suppl 6, S7S12.Google ScholarPubMed
68Unger, T & Gohlke, P (1990) Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors. Am J Cardiol 65, 3I10I.CrossRefGoogle Scholar
69De Gasparo, M (2002) AT(1) and AT(2) angiotensin II receptors: key features. Drugs 1, 110.CrossRefGoogle Scholar
70Ouchi, N, Kihara, S, Funahashi, T, et al. (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14, 561566.CrossRefGoogle ScholarPubMed
71Hotamisligil, GS, Shargill, NS & Spiegelman, BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 8791.CrossRefGoogle ScholarPubMed
72Hotamisligil, GS, Arner, P, Caro, JF, et al. (1995) Increased adipose tissue expression of tumor necrosis-alpha in human obesity and insulin resistance. J Clin Invest 95, 24092415.CrossRefGoogle Scholar
73Perreault, M & Marette, A (2001) Targeted disruption of inducible nitric oxide synthase protects against obesity-linked insulin resitance in muscle. Nat Med 7, 11381143.CrossRefGoogle Scholar
74Wlodek, D & Gonzales, M (2003) Decreased energy levels can cause and sustain obesity. J Theor Biol 225, 3344.CrossRefGoogle ScholarPubMed
75Boudina, S, Sena, S, O'Neill, BT, et al. (2005) Reduced mitochondrial oxidative capacity and increased mitochondrial uncoupling impair myocardial energetic in obesity-linked insulin resistance in muscle. Circulation 112, 26862695.CrossRefGoogle Scholar
76Munzberg, H & Myers, MC (2005) Molecular and anatomical determinants of central leptin resistance. Nat Neurosci 8, 566570.CrossRefGoogle ScholarPubMed
77Tilg, H & Moschen, AR (2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 6, 772773.CrossRefGoogle ScholarPubMed
78Picchi, A, Gao, X, Belmadani, S, et al. (2006) Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res 99, 6977.CrossRefGoogle ScholarPubMed
79Reaven, GM, Chang, H, Hoffman, BB, et al. (1989) Resistance to insulin-stimulated glucose uptake in adipocytes isolated from spontaneously hypertensive rats. Diabetes 38, 11551160.CrossRefGoogle ScholarPubMed
80Hulman, S, Falkner, B & Chen, YQ (1991) Insulin resistance in the spontaneously hypertensive rat. Metabolism 40, 359361.CrossRefGoogle ScholarPubMed
81Aitman, TJ, Gotoda, T, Evans, AL, et al. (1997) Quantitative trait loci for cellular defects in glucose and fatty acid metabolism in hypertensive rats. Nat Genet 16, 197201.CrossRefGoogle ScholarPubMed
82Aitman, TJ, Glazier, AM, Wallace, CA, et al. (1999) Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet 21, 7683.CrossRefGoogle ScholarPubMed
83Kvetnanský, R, Rusnák, M, Gasperíková, D, et al. (1997) Hyperinsulinemia and sympathoadrenal system activity in the rat. Ann N Y Acad Sci 827, 118134.CrossRefGoogle ScholarPubMed
84Ishizuka, T, Ernsberger, P, Liu, S, et al. (1998) Phenotypic consequences of a nonsense mutation in the leptin receptor gene (fak) in obese spontaneously hypertensive Koletsky rats (SHROB). J Nutr 128, 22992306.CrossRefGoogle Scholar
85Ernsberger, P, Ishizuka, T, Liu, S, et al. (1999) Mechanisms of antihyperglycemic effects of moxonidine in the obese spontaneously hypertensive Koletsky rat (SHROB). J Pharmacol Exp Ther 288, 139147.Google Scholar
86Koletsky, S (1973) Obese spontaneously hypertensive rats – a model for study of atherosclerosis. Exp Mol Pathol 19, 5360.CrossRefGoogle ScholarPubMed
87Koletsky, S (1975) Pathologic findings and laboratory data in a new strain of obese hypertensive rats. Am J Pathol 80, 129142.Google Scholar
88Kastin, AJ, Pan, W, Maness, LM, et al. (1999) Decreased transport of leptin across the blood–brain barrier in rats lacking the short form of the leptin receptor. Peptides 20, 14491453.CrossRefGoogle ScholarPubMed
89Koletsky, S (1975) Animal model: obese hypertensive rat. Am J Pathol 81, 463466.Google ScholarPubMed
90Michaelis, OE, Ellwood, KC, Judge, JM, et al. (1984) Effect of dietary sucrose on the SHR/N-corpulent rat: a new model for insulin-independent diabetes. Am J Clin Nutr 39, 612618.CrossRefGoogle ScholarPubMed
91Michaelis, OE, Patrick, DH, Hansen, CT, et al. (1986) Insulin-independent diabetes mellitus (type II). Spontaneous hypertensive/NIH-corpulent rat. Am J Pathol 123, 398400.Google ScholarPubMed
92Michaelis, OE, Carswell, N, Velasquez, MT, et al. (1989) The role of obesity, hypertension and diet in diabetes and its complications in the Spontaneous Hypertensive/NIH-corpulent rat. Nutrition 5, 5659.Google ScholarPubMed
93Wexler, BC, Iams, SG & McMurtry, JP (1980) Pathophysiological differences between obese and non-obese spontaneously hypertensive rats. Br J Exp Pathol 61, 195207.Google ScholarPubMed
94Hiraoka, J, Hosoda, K, Ogawa, Y, et al. (1997) Augmentation of obese (ob) gene expression and leptin secretion in obese spontaneously hypertensive rats (obese SHR or Koletsky rats). Biochem Biophys Res Commun 231, 582585.CrossRefGoogle Scholar
95Baly, DL, Zarnowski, MJ, Carswell, N, et al. (1989) Insulin resistant glucose transport activity in adipose cells from the SHR/N-corpulent rat. J Nutr 119, 628632.CrossRefGoogle ScholarPubMed
96Striffler, JS, Bhathena, SJ, Michaelis, OE, et al. (1998) Long-term effects of perindopril on metabolic parameters and the heart in the spontaneously hypertensive/NIH-corpulent rat with non-insulin-dependent diabetes mellitus and hypertension. Metabolism 47, 11991204.CrossRefGoogle ScholarPubMed
97Velasquez, MT, Kimmel, PL, Michaelis, OE 4th, et al. (1989) Effect of carbohydrate intake on kidney function and structure in SHR/N-cp rats. A new model of NIDDM. Diabetes 38, 679685.CrossRefGoogle ScholarPubMed
98Triana, RJ, Suits, GW, Garrison, S, et al. (1991) Inner ear damage secondary to diabetes mellitus. I. Changes in adolescent SHR/N-cp rats. Arch Otolaryngol Head Neck Surg 117, 635640.CrossRefGoogle ScholarPubMed
99Turley, SD & Hansen, CT (1986) Rates of sterol synthesis in the liver and extrahepatic tissues of the SHR/N-corpulent rat, an animal with hyperlipidemia and insulin-independent diabetes. J Lipid Res 27, 486496.Google ScholarPubMed
100Yamori, Y, Ohtaka, M, Horie, R, et al. (1978) Cerebral stroke and myocardial lesions in stroke-prone SHR. Jpn Heart J 19, 609611.CrossRefGoogle ScholarPubMed
101Collins, HL, Rodenbaugh, DW & DiCarlo, SE (2000) Daily exercise attenuates the development of arterial blood pressure related cardiovascular risk factors in hypertensive rats. Clin Exp Hypertens 22, 193202.CrossRefGoogle ScholarPubMed
102Hiraoka-Yamamoto, J, Nara, Y, Yasui, N, et al. (2004) Establishment of a new animal model of metabolic syndrome: SHRSP fatty (fa/fa) rats. Clin Exp Pharmacol Physiol 31, 107109.CrossRefGoogle ScholarPubMed
103Marchesini, G, Brizi, M, Bianchi, G, et al. (2001) Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50, 18441850.CrossRefGoogle ScholarPubMed
104Marchesini, G, Bianchi, G, Merli, M, et al. (2003) Nutritional supplementation with branched-chain amino acids in advanced cirrhosis: a double-blind, randomized trial. Gastroenterology 124, 17921801.CrossRefGoogle ScholarPubMed
105den Boer, M, Voshol, PJ, Kuipers, F, et al. (2004) Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol 24, 644649.CrossRefGoogle ScholarPubMed
106Diehl, AM (2004) Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis 8, 619638.CrossRefGoogle ScholarPubMed
107Qi, NR, Wang, J, Zidek, V, et al. (2005) A new transgenic rat model of hepatic steatosis and the metabolic syndrome. Hypertension 45, 10041011.CrossRefGoogle ScholarPubMed
108Samuel, VT, Liu, ZX, Qu, X, et al. (2004) Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279, 32 34532 353.CrossRefGoogle ScholarPubMed
109Horton, JD, Goldstein, JL & Brown, M (2002) SSREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109, 11251131.CrossRefGoogle Scholar
110Horton, JD, Goldstein, JL & Brown, M (2002) SSREBPs: transcriptional mediators of lipid homeostasis. Cold Spring Harb Symp Quant Biol 67, 491498.CrossRefGoogle Scholar
111Horton, JD, Shimomura, I, Ikemoto, S, et al. (2003) Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver. J Biol Chem 278, 36 65236 660.CrossRefGoogle ScholarPubMed
112Filippetti, R, Kloting, I, Massi, M, et al. (2007) Involvement of cocaine-amphetamine regulated transcript in the differential feeding responses to nociceptin/orphanin FQ in dark agouti and Wistar Ottawa Karlsburg W rats. Peptides 28, 19661973.CrossRefGoogle ScholarPubMed
113van den Brandt, J, Kovács, P & Klöting, I (2000) Features of the metabolic syndrome in the spontaneously hypertriglyceridemic Wistar Ottawa Karlsburg W (RT1u Haplotype) rat. Metabolism 49, 11401144.CrossRefGoogle ScholarPubMed
114van den Brandt, J, Kovács, P & Klöting, I (2000) Metabolic features in disease-resistant as well as in spontaneously hypertensive rats and newly established obese Wistar Ottawa Karlsburg inbred rats. Int J Obes Relat Metab Disord 24, 16181622.CrossRefGoogle ScholarPubMed
115Klöting, I, Kovács, P & van den Brandt, J (2001) Sex-specific and sex-independent quantitative trait loci for facets of the metabolic syndrome in WOKW rats. Biochem Biophys Res Commun 284, 150156.CrossRefGoogle ScholarPubMed
116Kovács, P, van den Brandt, J & Klöting, I (2000) Genetic dissection of the syndrome X in the rat. Biochem Biophys Res Commun 269, 660665.CrossRefGoogle ScholarPubMed
117Klöting, I, Vogt, L & Serikawa, T (1995) Locus on chromosome 18 cosegregates with diabetes in the BB/OK rat subline. Diabete Metab 21, 338344.Google ScholarPubMed
118Grisk, O, Frauendorf, T, Schlüter, T, et al. (2007) Impaired coronary function in Wistar Ottawa Karlsburg W rats – a new model of the metabolic syndrome. Pflugers Arch 454, 10111021.CrossRefGoogle ScholarPubMed
119Wisløff, U, Najjar, SM, Ellingsen, O, et al. (2005) Cardiovascular risk factors emerge after artificial selection for low aerobic capacity. Science 307, 418420.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Abnormalities that characterise the different rat stains that could be used to study the metabolic syndrome

You have Access
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the or variations. ‘’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Experimental rat models to study the metabolic syndrome
Available formats

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

Experimental rat models to study the metabolic syndrome
Available formats

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

Experimental rat models to study the metabolic syndrome
Available formats

Reply to: Submit a response

Please enter your response.

Your details